Evidence map›Paper›PMID 38341607›Full record

ArticleJournal of psychoactive drugs

Psychedelic Microdosing among Young Adults from Southern California.

Alyssa F Harlow, Peter S Hendricks, Adam M Leventhal, Jessica L Barrington-Trimis

Abstract read
In one paragraph

Article in Journal of psychoactive drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alyssa F HarlowDepartment of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.ORCID 0000-0001-6744-6988
Peter S HendricksDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama School of Medicine, Birmingham, AL, USA.
Adam M LeventhalDepartment of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Jessica L Barrington-TrimisDepartment of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Funding

Vaping Nicotine and Cannabis Across Adolescence and Young AdulthoodR01CA229617 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BARRINGTON-TRIMIS, JESSICA LOUISE, LEVENTHAL, ADAM MATTHEW · 2019 to 2024
$4.3M
The Tobacco and Cannabis Retail Environment, Neighborhood Disadvantage, and Adolescent VapingK01DA058084 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Alyssa Fitzpatrick Harlow · 2023 to 2026
$752k
NCI NIH HHS R01 CA229617NIDA NIH HHS K01 DA058084
6 · The paper itself

Abstract

Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were correlated with having ever microdosed. Among 2,396 participants, 293 (12%) had heard of microdosing and 74 (3%) ever microdosed. Among those who had heard of microdosing, 79% correctly defined microdosing as taking an amount of a psychedelic much lower than a standard dose, whereas 15% misperceived microdosing as a standard psychedelic dose. Psilocybin was the most common drug ever microdosed (70%), followed by lysergic acid diethylamide (LSD, 57%). Among those who ever microdosed, ~18% reported using psychoactive doses far higher than would be generally considered a microdose. White race, male/masculine gender identity, bisexual identity, past 6-month other drug use, greater attention deficit/hyperactivity disorder symptoms, mindfulness, and sensation-seeking were positively associated with having ever microdosed in multivariable models. Young adult microdosing merits further attention from scientific and public health professionals to help prevent misperceptions and potential adverse consequences as well as explore its potential therapeutic applications.

Indexed as

HallucinogensHealth Knowledge, Attitudes, PracticeSubstance-Related DisordersAdolescentCaliforniaDose-Response Relationship, DrugFemaleHumansLysergic Acid DiethylamideMalePsilocybinYoung AdultHallucinogensLysergic Acid DiethylamidePsilocybinLSDMDMAmicrodosingpsilocybinpsychedelicsyoung adults

Identifiers

PMID38341607
PMCPMC11315810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.